Market Cap 540.42M
Revenue (ttm) 482.04M
Net Income (ttm) 860,000.00
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.18%
Debt to Equity Ratio 0.00
Volume 446,200
Avg Vol 714,958
Day's Range N/A - N/A
Shares Out 126.86M
Stochastic %K 76%
Beta 1.68
Analysts Strong Sell
Price Target $8.00

Company Profile

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 781 575 0775
Address:
85 Dan Road, Canton, United States
justkeepgoing
justkeepgoing Oct. 24 at 3:51 PM
0 · Reply
Mobagri
Mobagri Oct. 24 at 2:19 PM
$ORGO BLA meeting coming up
0 · Reply
Mobagri
Mobagri Oct. 24 at 2:16 PM
$ORGO like I said yesterday
1 · Reply
Mobagri
Mobagri Oct. 23 at 1:50 PM
$ORGO best opportunity to buy in the 4s before big announcements on November 6th. Wound care products taking over. RENU is a different animal.
0 · Reply
Monticello4
Monticello4 Oct. 22 at 10:25 PM
$ORGO Remember this post? FinancialScience - May 28, 2025 12:01 AM $MDXG any mdxg shareholder who does not swap their mdxg shares for orgo shares is a dummy Bearish Bbbbbbbbwwwwwwhahahahahahahahaha!!!!!!!!!!! 1
2 · Reply
CircleM
CircleM Oct. 21 at 2:51 PM
$ORGO being investigated for securities fraud… could see low $3’s
2 · Reply
Mobagri
Mobagri Oct. 20 at 4:51 AM
$ORGO mimedyx troll
0 · Reply
Mobagri
Mobagri Oct. 16 at 2:26 PM
$ORGO Submission of Renu most likely in January due to government shut down. PuraPly and Affinity to take big market share from competitors. New pipeline.
1 · Reply
Monticello4
Monticello4 Oct. 16 at 9:27 AM
$ORGO Time running out - high short interest - AVOID
1 · Reply
Mobagri
Mobagri Oct. 8 at 4:04 PM
$ORGO approaching Pre-BLA meeting. New FDA is Stem Cell friendly.
0 · Reply
Latest News on ORGO
Why Is Organogenesis Stock Trading Lower Friday?

Sep 26, 2025, 11:24 AM EDT - 4 weeks ago

Why Is Organogenesis Stock Trading Lower Friday?


Organogenesis Provides Update on Second Phase 3 ReNu® Study

Sep 25, 2025, 4:50 PM EDT - 4 weeks ago

Organogenesis Provides Update on Second Phase 3 ReNu® Study


Organogenesis Commends Final LCDs

Nov 15, 2024, 9:25 AM EST - 1 year ago

Organogenesis Commends Final LCDs


Organogenesis Shares ReNu® Program Update

Aug 8, 2024, 4:04 PM EDT - 1 year ago

Organogenesis Shares ReNu® Program Update


justkeepgoing
justkeepgoing Oct. 24 at 3:51 PM
0 · Reply
Mobagri
Mobagri Oct. 24 at 2:19 PM
$ORGO BLA meeting coming up
0 · Reply
Mobagri
Mobagri Oct. 24 at 2:16 PM
$ORGO like I said yesterday
1 · Reply
Mobagri
Mobagri Oct. 23 at 1:50 PM
$ORGO best opportunity to buy in the 4s before big announcements on November 6th. Wound care products taking over. RENU is a different animal.
0 · Reply
Monticello4
Monticello4 Oct. 22 at 10:25 PM
$ORGO Remember this post? FinancialScience - May 28, 2025 12:01 AM $MDXG any mdxg shareholder who does not swap their mdxg shares for orgo shares is a dummy Bearish Bbbbbbbbwwwwwwhahahahahahahahaha!!!!!!!!!!! 1
2 · Reply
CircleM
CircleM Oct. 21 at 2:51 PM
$ORGO being investigated for securities fraud… could see low $3’s
2 · Reply
Mobagri
Mobagri Oct. 20 at 4:51 AM
$ORGO mimedyx troll
0 · Reply
Mobagri
Mobagri Oct. 16 at 2:26 PM
$ORGO Submission of Renu most likely in January due to government shut down. PuraPly and Affinity to take big market share from competitors. New pipeline.
1 · Reply
Monticello4
Monticello4 Oct. 16 at 9:27 AM
$ORGO Time running out - high short interest - AVOID
1 · Reply
Mobagri
Mobagri Oct. 8 at 4:04 PM
$ORGO approaching Pre-BLA meeting. New FDA is Stem Cell friendly.
0 · Reply
Monticello4
Monticello4 Oct. 7 at 7:55 PM
$ORGO Short Interest continues to rise. Cash running low. AVOID.
1 · Reply
Mobagri
Mobagri Oct. 6 at 11:46 PM
$ORGO starting January PuraPly will take market share from Epifix of Mimidyx.
0 · Reply
Monticello4
Monticello4 Oct. 6 at 9:49 PM
$ORGO Short interest climbing higher. AVOID
1 · Reply
ProposalPatrol
ProposalPatrol Oct. 5 at 3:57 PM
$ORGO Technology services micro-cap. No pattern recognition. Illiquid conditions. Avoid.
0 · Reply
Mobagri
Mobagri Oct. 1 at 11:38 AM
$ORGO In 2026 they won’t have the 50M expense for the phase 3 trial, so income technically should be 50M more. Big difference
1 · Reply
MaxProfitTrades
MaxProfitTrades Sep. 30 at 1:51 PM
$ORGO who caught the dip 😎
0 · Reply
josegodoy
josegodoy Sep. 30 at 1:00 PM
$ORGO recently a challenge of/towards the 200-day line have been a pretty bet for the bulls….5th times the charm?
1 · Reply
Cutz7
Cutz7 Sep. 26 at 9:48 PM
$ORGO there’s no way this gets on formulary anywhere. Insurances won’t cover anything without a statistically significant result. DOA
0 · Reply
Mobagri
Mobagri Sep. 26 at 3:42 PM
$ORGO • 🧾 AI analysis: 1. Consistency of direction • Trial 1: met primary endpoint (p=0.0177). • Trial 2: numerical benefit, narrowly missed prespecified alpha (p=0.0393 vs 0.023). • Both show directionally consistent benefit. 2. Pooled analysis • Pre-specified IPD pooled SAP: combined data statistically significant for pain reduction. • Clinically meaningful effect size: ≥0.5 WOMAC units → exceeds MCID thresholds. 3. Responder rates • ≥30% and ≥50% pain reduction responder rates: strong separation vs saline, • significant improvement in function (Trial 2 function endpoint p<0.0001). • safe: no RPOA, no accelerated structural damage, no new safety signals. • Favorable compared to corticosteroids, HA injections, and prior NGF inhibitors. • RMAT designation demonstrates FDA recognition of unmet need • Willing to accept narrower initial label (e.g., severe OA KL3–4) if that eases approval. • Commitment to post-marketing confirmatory trial to strengthen long-term data.
0 · Reply
Linda11S
Linda11S Sep. 26 at 3:09 PM
$ORGO 🤔
1 · Reply
Mobagri
Mobagri Sep. 26 at 1:39 PM
$ORGO The best thing they have going is the safety profile. When the FDA feels a drug is safe and do no harm, then they feel more comfortable giving conditional approval pending confirmatory trial. That’s my opinion.
2 · Reply
Mobagri
Mobagri Sep. 26 at 12:07 PM
$ORGO they should switch the primary endpoint to maintenance of functionality which was statistically very different. Group with Renu kept their knee function. If I were a patient that would be more important than mere pain cause I can pop a Tylenol for that but no treatment including injection in joints has maintained function as far as I know.
0 · Reply